Today: 10 June 2026
Browse Category

NYSE:PFE 22 November 2025 - 11 December 2025

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer shares traded near $25.78 early Thursday, flat from Wednesday’s close, after hedge fund Marshall Wace disclosed a 96.8% reduction in its stake. The stock remains over 50% below its December 2021 high. Pfizer’s 52-week range is $20.92 to $27.69, with a market cap near $147 billion and a dividend yield around 6.7%.
11 December 2025
··
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer shares traded near $25.5 on December 10, up less than 1% but still over 50% below their 2021 peak. The company announced a $2.1 billion obesity-drug partnership with China’s YaoPharma, reported Phase 3 wins for TUKYSA and HYMPAVZI, and confirmed new job cuts in Switzerland. Dividend yield stands near 6.7%. Pfizer reaffirmed 2025 adjusted EPS guidance at $3.00–$3.15.
10 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer shares closed down 1.7% at $25.33 on December 9, 2025, with volume below average. After hours, the stock edged up to $25.40 as investors reacted to Pfizer’s new global licensing deal with YaoPharma for an early-stage oral obesity drug. The agreement includes a $150 million upfront payment and potential milestones up to $2.1 billion.
10 December 2025
····
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer shares traded near $26 on December 8, 2025, with a market cap around $148 billion and a dividend yield of 6.6–7%. The stock remains down about 36% over five years and over 50% below its December 2021 peak. New Phase 3 hemophilia data, an obesity-drug acquisition, and AI-driven cost cuts drew investor attention. Year-to-date total return is flat to slightly positive, depending on dividend inclusion.
8 December 2025
···
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer shares closed at $26.03 on December 5, 2025, up 1.28% and 24% above April’s low. The stock yields about 6.6% with an annualized dividend of $1.72 per share and has paid 347 consecutive quarterly dividends. Pfizer’s Q3 revenue fell 6% to $16.65 billion, but adjusted EPS beat expectations at $0.87. The stock trades at 8–9x forward earnings, below the market average.
6 December 2025
···
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer shares traded near $26 late December 5, up about 1%, with a market cap of $146 billion and a dividend yield close to 7%. New analyst coverage flagged tighter FDA COVID vaccine rules and looming patent expirations for key drugs as risks. The stock remains 36% below its five-year level despite recent gains. Investors await updated 2026 guidance and details on a major obesity-drug acquisition.
5 December 2025
···
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer shares traded at $25.60 late December 3, 2025, near the midpoint of their 52-week range and well below 2021 highs. The stock yields about 6.5–7% and trades at 8–9x forward earnings after a $10 billion obesity-drug deal. Technical analysis points to support near $24.95 and resistance around $26.10. Market capitalization stands near $144 billion.
3 December 2025
···
Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer closed at $25.74 on November 28, with a market cap near $146 billion, down about 50% from its 2021–22 COVID peak. Q3 2025 revenue fell 6–7% to $16.7 billion as COVID sales declined, but adjusted EPS beat at $0.87. The company raised 2025 EPS guidance to $3.00–$3.15 and reaffirmed revenue targets. On September 30, Pfizer agreed to cut Medicaid drug prices in exchange for U.S. export tariff relief.
30 November 2025
··
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer shares closed at $25.74 on November 28, 2025, down 1.8% over the past year. Regulatory filings show new institutional buying, and the company completed a Metsera acquisition worth up to $10 billion. Pfizer reduced its BioNTech stake by 54.7% and raised its full-year EPS guidance to $3.00–$3.15 after reporting $16.7 billion in Q3 revenue.
30 November 2025
····
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer shares traded near $25.70 late Wednesday morning, down about 0.1%–0.2%. Zacks Research raised its 2025 earnings estimate for Pfizer to $3.15 per share, above Wall Street consensus. Thornburg Investment Management increased its Pfizer stake by 5.7% in Q2, now holding about 10.46 million shares. Pfizer’s next dividend payment is set for December 1.
26 November 2025
·
Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer closed Tuesday at $25.72, up nearly 2%, with a dividend yield of about 6.7% and a market cap near $146 billion. Unusual options activity clustered at the $25 strike followed new FDA approval for PADCEV plus Keytruda in bladder cancer and the completed Metsera obesity drug acquisition. Analyst target averages $28.56. Pfizer trades at a forward P/E of about 8.6, with 2025 total return up 3–4% year-to-date.
26 November 2025
··
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.
25 November 2025
···
Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

Pfizer shares traded near $25 late Monday, valuing the company at about $143 billion, with a dividend yield of roughly 6.8%. Q3 2025 revenue fell 6% to $16.7 billion, as COVID product sales declined sharply, but non-COVID portfolio sales rose 4%. Adjusted EPS of $0.87 beat expectations by over 30%. Pfizer reaffirmed 2025 revenue guidance and raised its adjusted EPS outlook.
25 November 2025
·
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer closed Friday at $25.04 per share, with a market cap near $140 billion and a dividend yield close to 7%. The company finalized a multibillion-dollar obesity drug acquisition, won a major U.S. cancer approval, issued $6 billion in bonds, and settled a $41.5 million lawsuit in Texas. Shares remain over 60% below pandemic highs. New analysis highlights both upside and ongoing risks.
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer closed Friday at $25.04, up 2.6%, with trading volume above 72 million shares. The company completed a $6 billion bond offering late Friday, spanning maturities from 2027 to 2065. Pfizer’s stock is down about 12% over the past year, despite a recent FDA cancer-drug approval and a multi-billion-dollar obesity drug deal. Dividend yield stands near 6.9%.
23 November 2025
···
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
1 … 5 6 7 8 9 10

Stock Market Today

  • Midday Stocks Movers: Super Micro Plunges, Cracker Barrel Surges, Robinhood Up 5%
    June 10, 2026, 2:55 PM EDT. Freight stocks fell sharply as Amazon announced its less-than-truckload shipping service will open to outside companies. FedEx Freight and Old Dominion Freight Line dropped 5%, XPO fell 4%. Super Micro Computer slumped 18% after a $7 billion equity raise plan to finance hardware purchases. Chip stocks like Micron, AMD, and Broadcom declined 4-5%. Devon Energy rallied over 6% post a bullish upgrade and positive update after a $58 billion acquisition. Cracker Barrel soared 24% after raising full-year guidance and reporting better-than-expected Q3 results. Casey's General Stores jumped 14% on strong quarterly earnings and fuel margin growth. Gambling stocks including DraftKings rose on optimistic outlooks. Robinhood Markets gained 5% after reporting higher platform assets and receiving regulatory approval as an IPO underwriter.

Latest articles

Webull Shares Climb; BULL Call Options Activity Rises as Retail Traders Pile In

Webull Shares Climb; BULL Call Options Activity Rises as Retail Traders Pile In

10 June 2026
Webull shares soared 11.9% to $6.16 as traders piled into short-dated call options, driving volume above average, following a recent FINRA rule change that eliminated the $25,000 minimum and day trade limits for small accounts—raising hopes for increased trading activity but leaving questions about whether higher costs will offset potential revenue gains.
Battalion Oil Shares Surge 50% on Heavy BATL Trading Ahead of Annual Meeting

Battalion Oil Shares Surge 50% on Heavy BATL Trading Ahead of Annual Meeting

10 June 2026
Battalion Oil shares soared 51% to $1.98 on record volume—over 120 million shares traded, more than five times shares outstanding—driven by speculation around its Monument Draw drilling plan, pending refinancing talks, and Thursday’s annual meeting, with no new earnings released and risks of dilution and compliance challenges still looming.
Go toTop